Exact Sciences (NASDAQ:EXAS) PT Lowered to $60.00 at Craig Hallum

Exact Sciences (NASDAQ:EXASGet Rating) had its price objective lowered by Craig Hallum from $81.00 to $60.00 in a research report sent to investors on Wednesday morning, MarketBeat.com reports. Craig Hallum currently has a buy rating on the medical research company’s stock.

A number of other analysts have also weighed in on the company. Robert W. Baird reduced their target price on Exact Sciences from $100.00 to $90.00 in a research note on Wednesday, April 27th. Cowen set a $83.00 price target on Exact Sciences in a research note on Tuesday, July 19th. StockNews.com upgraded Exact Sciences from a sell rating to a hold rating in a research note on Tuesday, July 26th. Citigroup cut their price target on Exact Sciences from $80.00 to $65.00 in a research note on Wednesday, April 27th. Finally, The Goldman Sachs Group cut their price target on Exact Sciences from $100.00 to $85.00 and set a buy rating on the stock in a research note on Tuesday, April 19th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $73.09.

Exact Sciences Trading Down 4.7 %

EXAS stock opened at $47.05 on Wednesday. The company has a current ratio of 2.48, a quick ratio of 2.29 and a debt-to-equity ratio of 0.70. The business’s fifty day simple moving average is $44.58 and its two-hundred day simple moving average is $59.00. Exact Sciences has a twelve month low of $35.34 and a twelve month high of $108.99.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of Exact Sciences stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total value of $208,005.12. Following the transaction, the director now owns 60,318 shares in the company, valued at $2,722,754.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the firm’s stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total value of $208,005.12. Following the completion of the sale, the director now owns 60,318 shares of the company’s stock, valued at $2,722,754.52. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Katherine S. Zanotti sold 1,086 shares of the firm’s stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $40.13, for a total value of $43,581.18. Following the completion of the sale, the director now directly owns 60,318 shares of the company’s stock, valued at approximately $2,420,561.34. The disclosure for this sale can be found here. Insiders have sold 5,701 shares of company stock worth $251,872 over the last quarter. Insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On Exact Sciences

Several institutional investors have recently added to or reduced their stakes in EXAS. Janney Montgomery Scott LLC boosted its holdings in Exact Sciences by 15.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 12,780 shares of the medical research company’s stock worth $995,000 after acquiring an additional 1,705 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in Exact Sciences by 1.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 73,856 shares of the medical research company’s stock worth $5,748,000 after acquiring an additional 1,338 shares in the last quarter. CWM LLC acquired a new stake in shares of Exact Sciences during the fourth quarter worth about $452,000. Quadrant Capital Group LLC lifted its holdings in shares of Exact Sciences by 23.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,315 shares of the medical research company’s stock worth $102,000 after purchasing an additional 253 shares during the period. Finally, FDx Advisors Inc. lifted its holdings in shares of Exact Sciences by 8.5% during the fourth quarter. FDx Advisors Inc. now owns 10,023 shares of the medical research company’s stock worth $780,000 after purchasing an additional 788 shares during the period. Institutional investors and hedge funds own 94.45% of the company’s stock.

About Exact Sciences

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Recommended Stories

Analyst Recommendations for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.